Suggested remit - To appraise the clinical and cost effectiveness of ticagrelor within its marketing authorisation for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease
As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
 
Status Suspended
Decision Selected
Process STA 2018
ID number 1514

Project Team

Project lead Louise Jafferally

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
09 August 2021 Suspended. As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
19 September 2019 In progress. In progress
19 September 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease. Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course.
14 January 2019 (10:00) Scoping workshop (Manchester)
16 November 2018 - 14 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual